To market transplant therapy - Grafalon
Zydus Group has entered into an in-licensing agreement with Neovii, a Switzerland based global bio-pharmaceutical company to launch Grafalon, an immunosuppressant extensively used in solid organ transplant and Stem Cell Transplant in India.Zydus will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
